It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The aim of this study was to evaluate whether (preoperative) plasma levels of fibrinogen, an essential clotting and acute phase protein, are associated with the prognosis of patients with a liposarcoma, a subtype of sarcoma derived from adipose tissue. We performed a retrospective cohort study of 158 patients with liposarcoma treated at the Department of Orthopaedics of the Medical University of Vienna in Austria from May 1994 to October 2021. Kaplan–Meier curves as well as uni- and multivariable Cox proportional hazard models were performed to evaluate the association between fibrinogen levels and overall survival. Elevated fibrinogen was associated with adverse overall survival in cause specific hazards analysis of mortality (hazard ratio [HR] per 10 mg/dL increase: 1.04; 95% CI 1.02–1.06; p < 0.001). This association prevailed in multivariable analysis after adjustment for AJCC tumor stage (HR 1.03; 95% CI 1.01–1.05; p = 0.013). Increasing levels of fibrinogen, a routinely available and inexpensive parameter, predicts the risk of mortality in patients with liposarcoma.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Medical University of Vienna, Department of Orthopaedics, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
2 Medical University of Vienna, Department of Radiation Oncology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
3 Medical University of Vienna, Clinical Institute of Pathology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
4 Medical University of Vienna, Department of Medicine I, Clinical Division of Oncology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
5 Medical University of Vienna, Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)